PL214869B1 - Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol - Google Patents

Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol

Info

Publication number
PL214869B1
PL214869B1 PL375632A PL37563203A PL214869B1 PL 214869 B1 PL214869 B1 PL 214869B1 PL 375632 A PL375632 A PL 375632A PL 37563203 A PL37563203 A PL 37563203A PL 214869 B1 PL214869 B1 PL 214869B1
Authority
PL
Poland
Prior art keywords
roflumilast
formoterol
pharmacologically acceptable
acceptable salt
administered
Prior art date
Application number
PL375632A
Other languages
English (en)
Polish (pl)
Other versions
PL375632A1 (en
Inventor
Rolf Beume
Daniela Bundschuh
Degenhard Marx
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of PL375632A1 publication Critical patent/PL375632A1/xx
Publication of PL214869B1 publication Critical patent/PL214869B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL375632A 2002-11-27 2003-11-26 Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol PL214869B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026504 2002-11-27

Publications (2)

Publication Number Publication Date
PL375632A1 PL375632A1 (en) 2005-12-12
PL214869B1 true PL214869B1 (pl) 2013-09-30

Family

ID=32338001

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375632A PL214869B1 (pl) 2002-11-27 2003-11-26 Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol

Country Status (31)

Country Link
US (1) US20060199865A1 (cg-RX-API-DMAC7.html)
EP (1) EP1567140B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006508993A (cg-RX-API-DMAC7.html)
KR (1) KR20050094810A (cg-RX-API-DMAC7.html)
CN (1) CN1713902A (cg-RX-API-DMAC7.html)
AT (1) ATE399544T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003288169B8 (cg-RX-API-DMAC7.html)
BR (1) BR0316475A (cg-RX-API-DMAC7.html)
CA (1) CA2506956C (cg-RX-API-DMAC7.html)
CO (1) CO5690571A2 (cg-RX-API-DMAC7.html)
CY (1) CY1110368T1 (cg-RX-API-DMAC7.html)
DE (1) DE60321954D1 (cg-RX-API-DMAC7.html)
DK (1) DK1567140T3 (cg-RX-API-DMAC7.html)
EA (1) EA009990B1 (cg-RX-API-DMAC7.html)
ES (1) ES2309374T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20050580B1 (cg-RX-API-DMAC7.html)
IL (1) IL168307A (cg-RX-API-DMAC7.html)
IS (1) IS2576B (cg-RX-API-DMAC7.html)
MA (1) MA27538A1 (cg-RX-API-DMAC7.html)
ME (1) ME00488B (cg-RX-API-DMAC7.html)
MX (1) MXPA05005438A (cg-RX-API-DMAC7.html)
NO (1) NO334148B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ540658A (cg-RX-API-DMAC7.html)
PL (1) PL214869B1 (cg-RX-API-DMAC7.html)
PT (1) PT1567140E (cg-RX-API-DMAC7.html)
RS (1) RS51082B (cg-RX-API-DMAC7.html)
SI (1) SI1567140T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN05130A1 (cg-RX-API-DMAC7.html)
UA (1) UA83017C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004047828A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200503307B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
CN103784443A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 一种包含沙美特罗和罗氟司特的药物组合产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
EP0938467B1 (en) * 1996-11-11 2002-06-12 Sepracor, Inc. Process for the preparation of optically pure isomers of formoterol
EA001758B1 (ru) * 1997-02-17 2001-08-27 Бык Гульден Ломберг Хемише Фабрик Гмбх Композиции для лечения респираторного дистресс-синдрома взрослых или респираторного дистресс-синдрома новорожденных, содержащие 3-(циклопропилметокси)-n-(3,5-дихлор-4-пиридинил)-4-(дифторметокси)бензамид и легочное поверхностно-активное вещество
US6333354B1 (en) * 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
EP1671651B1 (en) * 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
ES2314052T3 (es) * 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.

Also Published As

Publication number Publication date
EA200500865A1 (ru) 2005-12-29
EA009990B1 (ru) 2008-04-28
MXPA05005438A (es) 2005-08-03
US20060199865A1 (en) 2006-09-07
AU2003288169B2 (en) 2010-01-07
MA27538A1 (fr) 2005-09-01
CA2506956A1 (en) 2004-06-10
KR20050094810A (ko) 2005-09-28
AU2003288169B8 (en) 2010-08-26
ATE399544T1 (de) 2008-07-15
AU2003288169A1 (en) 2004-06-18
BR0316475A (pt) 2005-10-11
NO20053023L (no) 2005-06-20
PT1567140E (pt) 2008-09-24
ME00488B (me) 2011-10-10
RS51082B (sr) 2010-10-31
DE60321954D1 (de) 2008-08-14
EP1567140A1 (en) 2005-08-31
IL168307A (en) 2010-12-30
ES2309374T3 (es) 2008-12-16
RS20050383A (sr) 2007-08-03
IS7899A (is) 2005-06-20
SI1567140T1 (sl) 2008-12-31
CY1110368T1 (el) 2015-04-29
CN1713902A (zh) 2005-12-28
IS2576B (is) 2010-02-15
HRP20050580A2 (en) 2006-08-31
TNSN05130A1 (en) 2007-05-14
WO2004047828A1 (en) 2004-06-10
EP1567140B1 (en) 2008-07-02
HK1081862A1 (en) 2006-05-26
JP2006508993A (ja) 2006-03-16
CA2506956C (en) 2012-10-02
PL375632A1 (en) 2005-12-12
DK1567140T3 (da) 2008-11-03
NZ540658A (en) 2007-03-30
ZA200503307B (en) 2006-11-29
UA83017C2 (uk) 2008-06-10
NO334148B1 (no) 2013-12-16
CO5690571A2 (es) 2006-10-31
HRP20050580B1 (hr) 2014-04-11

Similar Documents

Publication Publication Date Title
PL200923B1 (pl) Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CA2506962C (en) Synergistic combination comprising roflumilast and formoterol
CA2519682A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
PL211574B1 (pl) Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego
PL214869B1 (pl) Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
WO2004084894A1 (en) Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol